Management

Donald J. McCaffreyPresident and Chief Executive Officer

As President and Chief Executive Officer of Zenith, Mr. McCaffrey has 40+ years of corporate management experience including over 20 years in drug discovery and development. Don’s expertise in corporate operations has attracted an international team of experts, including world renowned oncology Key Opinion Leaders. He has facilitated many high-profile collaborations and partnerships with leading organizations including Pfizer, Newsoara BioPharm Co., Ltd. (Newsoara), National Cancer Institute (NCI), University of California San Francisco (UCSF) and Merck.

In addition to Zenith, Don serves as President and CEO of Resverlogix Corp. (TSX: RVX), (“Resverlogix”), a late-stage clinical biotechnology company. Resverlogix has the most advanced epigenetic drug, apabetalone, which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in 2020, the first for a major cardiovascular indication. Zenith was spun out of Resverlogix in 2013.

Don is passionate about supporting local non-profit organizations, including: the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.

 

Sanjay Lakhotia, Ph.D., MBAChief Business Officer

Dr. Lakhotia serves as the Chief Business Officer and heads the development function at Zenith. Sanjay has been instrumental in recent collaborations and partnerships for Zenith – including Pfizer, NCI, UCSF, Merck, and Newsoara – which have helped to significantly advance and expand the clinical pipeline of ZEN-3694 in various cancer indications. He has also led Zenith’s programs from Investigational New Drug filings to mid-stage clinical trials.

Sanjay brings over 25 years of experience in corporate development, product development and strategy at leading biotechnology and pharmaceutical companies. Between 2010 and 2013, he led corporate development at Pathway Therapeutics, a clinical stage cancer and autoimmune company. Prior to Pathway, Sanjay was Senior Director of Corporate Development at Portola Pharmaceuticals, where his responsibilities included product licensing and program leadership. While at Portola, he contributed to the partnering of a significant Phase 2 asset and championed the development of an important cardiovascular drug now marketed in North America.

Prior to joining Portola in 2006, Sanjay held corporate development positions of increasing responsibility at Onyx Pharmaceuticals and MedImmune where he led the execution of several product and technology licensing transactions. Before transitioning to corporate development, he led process development groups at Wyeth Pharmaceuticals and Baxter contributing to the development of important vaccines, Prevnar and Meningetec.

Dr. Lakhotia obtained his Ph.D. in Biochemical Engineering at Northwestern University, an MBA from University of North Carolina, Chapel Hill, and BS in chemical engineering from the University of California, Berkeley.

 

Brad Cann, CPA, CA, CBVChief Financial Officer

Mr. Cann serves as Chief Financial Officer of Zenith, where he is responsible for overseeing corporate finance, financial reporting, corporate governance and operations. With over 25 years of experience, Brad possesses a wealth of knowledge in a variety of financial and corporate roles. Brad has also served as the Chief Financial Officer of Resverlogix Corp. (TSX:RVX), a leading, late-stage clinical epigenetics company, since 2009.

Previously, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust. Prior to his positions with Royal Host, he was a business consultant and held senior management positions with several companies including Chief Financial Officer of Sulphur Corporation of Canada Ltd. Prior thereto, Brad held various positions with Kenway Mack Slusarchuk Stewart Chartered Accountants.

Brad is a Chartered Professional Accountant and a Chartered Business Valuator and holds a Bachelor of Commerce from the University of Saskatchewan.

 

Henrik C. Hansen, Ph.D.Senior Vice President of Operations

Dr. Hansen is Senior Vice President of Operations at Zenith. He is responsible for Zenith’s intellectual property portfolio, new technology and execution of strategic procedures to achieve corporate objectives. Henrik brings over 22 years of biotechnology experience from both academia and industry in basic research to drug discovery development. His areas of expertise include medicinal chemistry, carbohydrate chemistry, high throughput synthesis, process development, and manufacturing of drug substances and drug products under Good Manufacturing Practices (GMPs) for clinical use.

Henrik also serves as Vice President of Intellectual Property at Resverlogix Corp., to which he is the inventor of lead drug apabetalone (RVX-208).

Dr. Hansen holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 75 articles and meeting abstracts and is listed as an inventor of 12 patent families.

Ravi Jahagirdar, DVM, MSVice President, Pharmacology, Toxicology and Safety

Dr. Jahagirdar is the Vice President of Pharmacology, Toxicology and Safety at Zenith and has led the team for lead drug candidate ZEN-3694 from discovery to IND. Ravi has more than 20 years of experience from both academia and industry in drug discovery and development. His area of expertise includes animal physiology, pharmacology, toxicology, DMPK and basic research. He has been successful in recruiting scientists, building departments and managing projects from early discovery to pre-clinical and clinical development. Ravi has also been with Resverlogix since 2004, playing a key role in all aspects of the development of apabetalone, including strategic leadership in the implementation of developmental toxicology and preclinical/clinical pharmacology. Ravi held previous positions of increasing responsibility at University of Regina, and Tularik Inc. (Amgen).

Dr. Jahagirdar obtained his Doctor of Veterinary Medicine from Veterinary College, Bangalore and a MS in Molecular Biology/Microbiology from Memorial University, Newfoundland. His research has been published in many peer reviewed journals and has co-authored a textbook chapter and has numerous abstract presentations.

Lisa Bauman, MSVice President, Clinical Operations

Ms. Bauman is Vice President of Clinical Operations at Zenith, where she is responsible for the development, execution and management of clinical trials. As head of clinical operations, Lisa has led the global development of ZEN-3694 in different cancer indications. Lisa brings over 25 years of global experience in clinical operations and drug development, including execution and management of Phase 1, 2 and 3 clinical trials under ICH/GCP guidelines.

Building on a strong foundation attained at Bristol-Myers Squibb, Lisa pursued broader clinical development roles in biotechnology working with small pharma start-up companies. With her transition to Agouron Pharmaceuticals, (acquired by Warner Lambert and subsequently by Pfizer), she gained global clinical operations experience in all phases of development including the registration of Viracept® (nelfinavir). Lisa then transitioned to leading clinical operations at Anadys Pharmaceuticals (acquired by Roche), where she led the successful execution of the company’s first proof of concept trials supporting two IND approvals. Building and expanding her experience in clinical operations, she then moved into a role of consulting for several start-up companies before joining Zenith in 2015.    

Ms. Bauman has a MS in Biomedical Engineering from Vanderbilt University, Tennessee.

Eric Campeau, Ph.D., PMPVice President, Translational Biology

Dr. Campeau is the Vice President of Translational Biology at Zenith. His responsibilities include designing and implementing translational research programs to Zenith’s clinical studies and evaluating the data to decipher mechanism of action of Zenith’s drugs and associated patient pre-selection strategies.

Eric has nearly 30 years of biomedical research experience with several publications in the field of epigenetics, cancer, DNA repair and metabolism. He has been involved in the preclinical and clinical development of ZEN-3694 since the beginning of Zenith in 2013. Eric led teams of scientists in the design of proof of concept preclinical studies, combination strategies, and translational assays for the clinical trials of ZEN-3694 in various indications. Most notably, the Translational Medicine team made key contributions in the design of a patient pre-selection approach for a randomized metastatic castration resistant prostate cancer study.

Prior to joining Zenith, Dr. Campeau joined Resverlogix Corp. in 2011 as a Scientist.  He was previously an Instructor at the University of Massachusetts Medical School, and a Scientist at the Lawrence Berkeley National Laboratory. 

Dr. Campeau obtained is Ph.D. in Human Genetics at McGill University.